Health-care companies rose sharply after President Trump signed an executive order designed to lower what Americans pay for prescription drugs that offered pharmaceutical companies room for ...

Key TakeawaysGlobal pharmaceutical shares jumped in intraday trading Monday, reversing their pre-market declines, as ...

Merck & Co., Inc. (MRK) is currently at $79.17, up $3.20 or 4.21% --On pace for largest percent increase since March 27, 2024, when it rose 4.96% --Down 40.46% from its all-time closing high of ...

Halozyme Therapeutics posts strong Q1 2025 earnings with 35% revenue growth, robust pipeline, and rising royalties.

Shares of Alphamab Oncology plunged 14.4% to HK$6.28, leading declines in Hong Kong-listed pharmaceutical stocks.Meanwhile, ...

The latest canine otitis externa medication is the only FDA-approved, 1-dose, in-clinic treatment for Pseudomonas aeruginosa ...

A new manufacturing plant in De Soto will be a Center of Excellence for the global company, along with expanded R&D ...

Despite a risk for severe side effects, pembrolizumab has a record of improving recurrence-free survival that makes it an appealing treatment for advanced melanoma.

Merck has launched its 2025 Curiosity Cube tour, bringing hands-on STEM experiences to students across the world.

DE SOTO, Kan. (KCTV) - Merck Animal Health is betting big on De Soto, announcing an $895 million expansion Thursday that ...

Merck is expanding domestic manufacturing with a $895 million investment in its Kansas factory, one of several major projects ...

Merck Animal Health will build an $895 million capital expansion project and add 200 jobs at its De Soto manufacturing ...